---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-026699"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:06:14.144011+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# UroGen presents at Guggenheim Healthcare Talks on Feb 8, 2024; no specific facts in filing

## Summary
- Furnished a corporate presentation under Item 7.01 for the Guggenheim Healthcare Talks Conference on February 8, 2024.
- Presentation titled 'Developing Innovative Medicines to Treat Urothelial Cancers' – text of exhibit does not include detailed updates.
- No financial results, pipeline milestones, or guidance changes disclosed in the filing.
- UroGen's stock ticker is URGN; presentation is for investor audiences only.

## SEC filing metadata
- accession: 0001193125-24-026699
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524026699/0001193125-24-026699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524026699/d21038d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-026699
- JSON: https://secwatch.observer/filing/0001193125-24-026699.json
- Plain text: https://secwatch.observer/filing/0001193125-24-026699.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.